Kidney Res Clin Pract > Volume 40(2); 2021 > Article |
|
Funding
This work was supported by the Grant of HRH Princess Maha Chakri Sirindhorn Medical Center (contact number 435/2562).
Authors’ contributions
Conceptualization, Funding acquisition: CK
Data curation, Project administration: PP
Formal analysis: CK, SP, PP
Investigation: CK, PP, RY
Methodology: CK, PP
Visualization: CK, PP, TD
Writing–original draft: CK, PP, TP, KW, TD
Writing–review & editing: CK, TP, KW, TD
All authors read and approved the final manuscript.
Demographic variable |
Genotype |
p-value |
||||
---|---|---|---|---|---|---|
GG (n = 40) | GC (n = 38) | CC (n = 12) | GG vs. GC | GG vs. CC | GC vs. CC | |
Sex, male:female | 26:14 | 21:17 | 3:9 | 0.04* | ||
Age (yr) | 60.0 ± 14.3 | 64.0 ± 9.8 | 59.8 ± 17.3 | 0.18 | 0.95 | 0.33 |
Duration of type 2 DM (yr) | 13.9 ± 10.0 | 13.3 ± 8.9 | 15.3 ± 9.3 | 0.79 | 0.67 | 0.54 |
Proteinuria at biopsy (g/g) | 3.04 (0.44–10.65) | 3.71 (0.53–23.80) | 3.76 (0.57–15.04) | 0.52 | 0.65 | 0.98 |
Diabetic retinopathy | 22 (55.0) | 17 (44.7) | 5 (41.7) | 0.57 | ||
Peripheral neuropathy | 23 (57.5) | 21 (55.3) | 8 (66.7) | 0.78 | ||
Macrovascular complicationa | 15 (37.5) | 11 (28.9) | 3 (25.0) | 0.61 | ||
SBP (mmHg) | 138.9 ± 14.8 | 138.3 ± 17.5 | 143.1 ± 18.6 | 0.90 | 0.41 | 0.47 |
DBP (mmHg) | 77.5 ± 9.8 | 75.4 ± 11.2 | 78.5 ± 21.0 | 0.49 | 0.82 | 0.48 |
HbA1C | 7.4 ± 1.7 | 6.9 ± 1.4 | 8.9 ± 3.2 | 0.49 | 0.45 | 0.23 |
Cr at biopsyb (mg/dL) | 1.38 (0.60–2.71) | 1.59 (0.69–2.80) | 1.46 (0.53–2.25) | 0.20 | 0.74 | 0.57 |
eGFR (CKD-EPI) at biopsyb (mL/min) | 60.3 (24.1–111.2) | 49.6 (16.0–99.0) | 55.1 (19.9–124.3) | 0.17 | 0.64 | 0.61 |
ESRD (dialysis dependent) | 18 (45.0) | 12 (31.6) | 4 (33.3) | 0.45 |
Data are expressed as number only, mean ± standard deviation, median (range), or number (%).
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation 1; Cr, serum creatinine; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HbA1C, hemoglobin A1c; SBP, systolic blood pressure.
Variable |
Overall (n = 90) |
Group with DR (n = 45) |
Group without DR (n = 45) |
||||||
---|---|---|---|---|---|---|---|---|---|
Odds ratio |
p-value |
Odds ratio |
p-value |
Odds ratio |
p-value |
||||
Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | ||||
Allele | |||||||||
C vs. G | 2.10 | 0.03* | 7.00 | 0.01* | 1.50 | 0.36 | |||
Genotype | pa = 0.02 | pa = 0.02 | pa = 0.49 | ||||||
CC vs. GG | 6.89 | 0.01* | 0.01* | 33.00 | 0.01* | 0.01* | 0.36 | 0.27 | NS |
CC vs. CG | 4.91 | 0.02* | NS | 24.00 | 0.01* | NS | 0.36 | 0.27 | NS |
CG vs. GG | 1.40 | 0.51 | NS | 1.38 | 0.83 | NS | 0.97 | 0.97 | NS |
Chatchai Kreepala
https://orcid.org/0000-0002-2615-4222
Pitirat Panpruang
https://orcid.org/0000-0003-2250-0607
Rapeeporn Yodprom
https://orcid.org/0000-0003-1541-0662
Teeraya Piyajarawong
https://orcid.org/0000-0001-8675-6682
Krittanont Wattanavaekin
https://orcid.org/0000-0001-8091-0319
Taechasit Danjittrong
https://orcid.org/0000-0002-5910-0941
Sadiporn Phuthomdee
https://orcid.org/0000-0003-2718-2652
Nondiabetic kidney diseases in type 2 diabetic patients2013 September;32(3)